Devyser Diagnostics (OM:DVYSR) Stock Turns Profitable On TTM EPS 0.92 Reinforcing Bullish Narratives
Devyser Diagnostics (OM:DVYSR) has reported Q2 2026 revenue of SEK60.2 million and net income of SEK1.6 million, equivalent to basic EPS of SEK0.10. The company has seen quarterly revenue range from SEK54.8 million in Q1 2025 to SEK72 million in Q4 2025, while basic EPS has moved from a loss of SEK1.24 per share in Q1 2025 to a profit of SEK0.92 per share on a trailing twelve month basis. This gives investors a clearer view of how the income statement has shifted over recent periods. Taken together, the latest quarter and the trailing twelve month figures highlight that profitability metrics are now central to assessing how sustainable the current margin profile may be.
See our full analysis for Devyser Diagnostics.With the latest earnings numbers on the table, the next step is to see how they line up against the widely followed narratives around Devyser Diagnostics and where those stories might be confirmed or challenged.
See what the community is saying about Devyser Diagnostics
Profitable Trailing Year, Softer Single Quarter
- On a trailing twelve month basis, Devyser Diagnostics has moved from a net loss of SEK69.8 million in Q1 2025 to net income of SEK15.4 million in Q2 2026, with basic EPS shifting from a loss of SEK4.24 per share to a profit of SEK0.92 per share.
- Consensus narrative expects revenue to grow about 16% per year with margins rising from 5.8% to 24.1%, and this profitability shift gives investors numbers to compare against those assumptions.
- Analysts project earnings to reach SEK96.9 million and EPS of SEK4.78 by around 2029, compared with SEK15.0 million of earnings in the latest trailing data, so the current SEK15.4 million profit is still far below those longer term targets.
- With the share price at SEK62.40 against an analyst price target of SEK120.82, the step into profit supports the more optimistic parts of the consensus view but also highlights how much growth is already baked into those expectations.
High P/E and Big Gap to DCF Fair Value
- The stock is trading on a trailing P/E of 68.4x versus 16.1x for the European Biotechs industry and 27.5x for peers, while a DCF fair value of SEK530.26 sits far above the current SEK62.40 share price.
- What stands out for the bullish view is the combination of a very high earnings multiple and a very large gap to DCF fair value, which pulls investors in two directions.
- Bulls point to forecast earnings growth of about 74.8% per year and revenue growth of about 19.9% per year as justification for paying 68.4x trailing earnings, yet those growth figures need to be weighed against the much lower 16.1x industry P/E.
- At the same time, the DCF fair value of SEK530.26 is many times the current SEK62.40 share price, so anyone leaning bullish has to decide whether the model assumptions behind that DCF are more persuasive than the market’s much lower pricing today.
Quarterly Earnings Ease, Bears Focus on Execution Risks
- Q2 2026 net income of SEK1.6 million and basic EPS of SEK0.10 follow Q1 2026 net income of SEK2.9 million and basic EPS of SEK0.17, alongside trailing twelve month revenue of SEK250.3 million and net income of SEK15.4 million.
- Critics highlight that, despite four quarters of positive EBIT and SEK12 million of operating cash flow, several factors from the bearish narrative could limit how much of this operating improvement converts into higher earnings.
- Bears point to continued spending on R&D and U.S. commercialization and to slightly lower near term margins on some Illumina reagent rental deals, which could cap further progress from the current SEK15.4 million of trailing net income even if revenue, at SEK250.3 million, continues to expand.
- They also flag execution risks around partner driven sales with Thermo Fisher and Quest and the relatively small current contribution from the CyberGene acquisition, arguing that any slower uptake through these channels would make the current high 68.4x P/E look demanding against the recent single quarter profit of SEK1.6 million.
Next Steps
To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Devyser Diagnostics on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.
After weighing both sides of the Devyser Diagnostics story, are you leaning more optimistic or cautious, and how firmly is that view grounded in the data in front of you? Take a moment to review the full risk and reward profile so you can decide how these findings fit your own thesis: 3 key rewards and 1 important warning sign.
See What Else Is Out There
For all the progress at Devyser Diagnostics, the combination of a high 68.4x P/E, softer recent quarterly earnings and execution risks around partnerships leaves plenty of question marks.
If that mix of rich pricing and uncertain follow through makes you uneasy, it is worth checking stocks with stronger value markers using the 232 high quality undervalued stocks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com